Immunicon Corporation engages in the development, manufacture, marketing, and sale of proprietary cell-based diagnostic and research products, and services with a focus on cancer. It develops technologies that identify, count, and characterize a small number of circulating tumor cells (CTC) and other rare cells present in a blood sample of a patient. The company offers CellSave Preservative Tube, an evacuated blood collection tube with preservative; CellTracks AutoPrep System, an automated instrument to capture and label cells from 7.5 ml blood samples; CellTracks MagNest Cell, a presentation device, which presents magnetically labeled cells for analysis; CellSpotter Analyzer; CellTracks Analyzer II, which is a semi-automated fluorescence microscope used to count and characterize cells; the CellSearch Circulating Tumor Cell Kit, which is used for counting CTCs in blood; CellSearch Profile Kit, which is used to isolate CTCs for subsequent molecular or cellular analysis; CellTracks Endothelial Cell Kit that is used in isolating and counting endothelial cells; CellTracks Bone Marrow Tumor Kit; Molecular diagnostic kits; and Tumor Phenotyping Reagents, which are research reagents for cell characterization. The company offers its products to hospitals, reference laboratories, clinical research organizations, and pharmaceutical/biotechnology companies in the United States, Europe, Japan, and Hong Kong. Immunicon has agreements with Veridex, LLC; KREATECH Biotechnology B.V.; Research and Diagnostic Systems, Inc.; and Pfizer, Inc. The company was founded in 1983 and is based in Huntingdon Valley, Pennsylvania.